Reuters logo
BRIEF-Bristol-Myers Opdivo plus Yervoy combination delivered overall survival benefit across PD-l1 expression levels
November 7, 2017 / 1:43 PM / in 12 days

BRIEF-Bristol-Myers Opdivo plus Yervoy combination delivered overall survival benefit across PD-l1 expression levels

Nov 7 (Reuters) - Bristol-myers Squibb Co

* Opdivo plus Yervoy combination delivered overall survival benefit across PD-l1 expression levels in intermediate- and poor-risk patients with previously untreated advanced or metastatic renal cell carcinoma

* Bristol-Myers Squibb Co - ‍Safety profile of Opdivo plus Yervoy was consistent with that of previous reports​

* Bristol-Myers Squibb - ‍Median OS was not reached for Opdivo plus Yervoy cobo or sunitinib for those with PD-l1 levels <1%, and for patients with PD-l1 expression levels ≥1% ​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below